Shocking lung cancer: new device zaps tumors without surgery
NCT ID NCT07638228
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early study tests a new device that uses electric pulses to destroy malignant lung nodules in people with early-stage lung cancer or limited lung metastases. Five participants will undergo a procedure where a needle is guided into the tumor using CT scans, then delivers electrical pulses to kill the cancer cells. The main goal is to see if the nodules are completely ablated one month after treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
5 people
The number who actually took part.
- Started
-
Sep 2025
- Expected to finish
-
Dec 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Age ≥ 18 years. 2. Subjects with malignant pulmonary nodules (confirmed by histopathology) planned for ablation therapy, including: 1. Stage IA primary non-small cell lung cancer; or 2. Intrapulmonary metastatic tumors with the primary lesion well controlled. 3. Solitary lesion size ≤ 2 cm, and total number of lesions ≤ 3. 4. ECOG performance status score ≤ 2. Patients who are ineligible for surgery/radiotherapy, or who refuse surgery/radiotherapy, or who voluntarily participate. Exclusion Criteria: A patient will be excluded from participation in this clinical trial if any of the following conditions apply: 1. Severe bleeding tendency, platelet count \< 50×10⁹/L, or coagulation dysfunction (prothrombin time \> 18 s, prothrombin activity \< 40%) that cannot be corrected in the short term. 2. Anticoagulant therapy and/or antiplatelet medications discontinued for less than 1 week prior to ablation. 3. Infectious or radiation-induced inflammation around the lesion, poorly controlled skin infection at the puncture site, systemic infection, or fever \> 38.5°C. 4. Severe dysfunction of the liver, kidney, heart, lung, or brain; severe anemia, dehydration, or serious nutritional/metabolic disorders that cannot be corrected or improved in the short term. 5. Poorly controlled malignant pleural effusion. 6. Distant metastasis of lung cancer. 7. Concurrent other malignancies with extensive metastasis, and expected survival \< 6 months. 8. Presence of implanted electronic devices near the target area, or an implanted cardiac pacemaker or defibrillator. 9. The target lesion has received prior local treatments (e.g., radiotherapy, ablation) within 3 months before enrollment. 10. Participation in any drug and/or medical device clinical trial within 1 month before enrollment. 11. Pregnancy, lactation, or planned pregnancy within one year. 12. Any other condition that the investigator considers inappropriate for enrollment.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Intrapulmonary metastatic tumors are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Sir Run Run Shaw Hospital, Zhejiang University School of Medicine
Hangzhou, Zhejiang, 310016, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Surgeons could freeze lung tumors from miles away using 5G robots
- Can AI make lung cancer scans easier to read?
- Two-Drug combo targets Treatment-Resistant lung cancer
- Can an Anti-Fibrotic drug shield lungs from radiation after immunotherapy?
- App aims to catch a hidden radiotherapy side effect
- Which nerve block wins for lung surgery pain?